Fig 1: Addition of LXRα agonist (A) T0901317 or (B) 22R-HC normalized IDOL and (C and D) reduced LDLR expression, respectively, in atorvastatin-treated THP-1 cells. Each bar represents the mean and SD of triplicate experiments. *P < 0.05 compared to non-treated cells, # P < 0.05 compared to atorvastatin-treated cells. The statistical significance of differences was determined using ANOVA followed by Bonferroni’s comparison.
Fig 2: Boxplots of serum levels of IDOL and PCSK9 in control and FH patients.
Fig 3: Addition of exogenous mevalonate overcomes atorvastatin-induced reduction in IDOL expression in THP-1 cells. Each bar represents the mean and s.d. of triplicate experiments. *P < 0.05 compared to non-treated cells, # P < 0.05 compared to atorvastatin-treated cells. The statistical significance of differences was determined using ANOVA followed by Bonferroni’s comparison.
Supplier Page from Abcam for Recombinant Human IDOL protein (His-DDDDK tag N-Terminus)